Food News and Research

RSS

Cepheid receives approval to market Xpert(R) HemosIL(R) FII & FV test

Cepheid and Instrumentation Laboratory (IL) today announced that Cepheid has received clearance from the U.S. Food & Drug Administration (FDA) to market its Xpert(R) HemosIL(R) FII & FV test.

25 Sep 2009

Partnership focused on improving health and reducing poverty in Haiti

Fonkoze, BRAC, BRAC USA, Partners In Health/Zanmi Lasante, CGAP, CHF partners in rural development and Linked Foundation have joined forces to commit $50 million towards a two-year effort to implement a proven, replicable, cost-effective approach to improving health and reducing extreme poverty in Central Haiti.

25 Sep 2009

FDA grants priority review for Cephalon's sNDA

Cephalon, Inc. today announced the U.S. Food and Drug Administration (FDA) has granted a priority review for its supplemental New Drug Application (sNDA) for NUVIGIL(R) (armodafinil) Tablets [C-IV], which was filed in June of this year.

25 Sep 2009

Attitude to weight and diet in teens dependent on social class

Teenagers' attitudes to diet and weight are shaped by their social class, according to new research funded by the Economic and Social Research Council. Policymakers have long insisted on the importance of understanding young people's health and eating habits but this is the first study to show how everyday practices and perceptions of different social classes contribute to variation in the diet, weight and health of teenagers.

25 Sep 2009

FA announces their Second Annual Fellowship Convention dates

Food Addicts in Recovery Anonymous (FA) announces their Second Annual Fellowship Convention to be held at the Santa Clara Marriot from October 16-18, 2009 in Santa Clara, California.

25 Sep 2009

Study on mitochondria function

For such crucial biological actors, much remains unknown about exactly how mitochondria function. A new study, published Aug. 12 in the online journal PLoS One, sheds light on mitochondrial biology. Using genetic engineering, researchers interrupted the activity of individual genes directly involved in the production of energy within mitochondria. "If we knock down the function of specific system components, what happens?" said study leader Marni J. Falk, M.D., who directs the Mitochondrial-Genetics Disease Clinic at The Children's Hospital of Philadelphia. "Our ultimate goal is to translate the knowledge into targeted therapies, that is, effective ways to intervene. But first we need to understand the underlying disease mechanisms."

25 Sep 2009

H1N1 influenza pandemic could present a host of medical ethics issues: JCB

The anticipated onset of a second wave of the H1N1 influenza pandemic could present a host of thorny medical ethics issues best considered well in advance, according to the University of Toronto Joint Centre for Bioethics, which today released nine papers for public discussion.

25 Sep 2009

Spherix's Annual Meeting of Shareholders to be held on November 17

Spherix Incorporated, an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its Annual Meeting of Shareholders will be held on November 17, 2009, at 9:00 a.m. Eastern time, at the Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, Maryland 20817.

24 Sep 2009

Walgreens ensures that all its pharmacies can provide Tamiflu

Less than a month after launching the largest flu prevention initiative in the company’s 108-year history, Walgreens is taking proactive measures to ensure its nearly 7,000 pharmacies can provide the suspension - or liquid - form of seasonal flu-fighting drug Tamiflu this season. Following Tamiflu manufacturer Roche’s notification that Tamiflu Oral Suspension is in short supply, Walgreens pharmacies in all 50 states are prepared to compound Tamiflu capsules into the liquid form to produce an Oral Suspension prescription. Tamiflu capsules remain in adequate supply.

24 Sep 2009

Regence offers coverage to meet the costs associated with H1N1

To remove financial barriers associated with administration of the H1N1 vaccine and to encourage members to seek vaccination, Regence BlueCross BlueShield will provide coverage for the costs associated with the administration of the H1N1 vaccine during the 2009-2010 flu season, waiving co-pays and deductibles for all members covered by its insured plans. Regence will strongly encourage self-insured employers to cover the full cost to ensure that the greatest number of people are protected.

24 Sep 2009

Octapharma AG submits Biological License Application for its octagam(R) 10% to FDA

Octapharma AG recently submitted its Biological License Application for octagam(R) 10% (human normal intravenous immunoglobulin, liquid) to the U.S. Food and Drug Administration (FDA) with the goal of expanding the biopharmaceutical company's U.S. immune globulin therapy portfolio by early 2010. The application was submitted for the treatment of Idiopathic Thrombocytopenic Purpura (ITP), a blood-clotting disorder that can result in excessive bruising and bleeding.

24 Sep 2009

Controlled release pills and capsules with dose dumping tendency should be tested

Controlled release pills and capsules that show a tendency in the standard laboratory test toward "dose dumping" - releasing their medicine in a faster and potentially unsafe manner in patients who have consumed alcohol - should be withheld from the market until proven safe with testing in people. That's the conclusion of a review of existing studies in the September-October issue of ACS' Molecular Pharmaceutics, a bi-monthly journal.

24 Sep 2009

CEL-SCI Corporation engages a CRO for clinical trial of its investigational LEAPS-H1N1 treatment

CEL-SCI Corporation (NYSE AMEX: CVM), a developer of vaccines and therapeutics for the treatment of infectious diseases and a late-stage oncology company, announced today that it has hired a full-service Clinical Research Organization (CRO) with an office in the Washington, D.C./Baltimore area to support its conduct of the upcoming clinical trial of its investigational LEAPS-H1N1 treatment.

24 Sep 2009

Rasagiline slows the rate of Parkinson's disease progression

Following one of the largest studies ever conducted in Parkinson's disease (PD), researchers at Mount Sinai School of Medicine report today in The New England Journal of Medicine that rasagiline, a drug currently used to treat the symptoms of PD, may also slow the rate of disease progression.

24 Sep 2009

Obama addresses U.N. General Assembly, calls for 'new era of engagement'

In his first U.N. General Assembly address, President Obama on Wednesday "called for 'a new era of engagement' ... with the world, pledging to work together with other countries while defending the interests of the United States," Reuters reports (9/23).

24 Sep 2009

46 million Americans uninsured

The uproar at this summer's raucous town hall meetings, Rep. Joe Wilson's outburst in Congress and the endless debate over whether some opposition to healthcare reform is racially-tinged are a major disservice to the millions of Americans who need healthcare reform. Rep. Wilson doesn't worry about costs if a member of his family falls ill; he is covered. The majority of the people screaming and waving signs at town hall meetings don't worry either. They are covered. Their family members walk into a doctor's office or hospital emergency room, flash insurance cards and receive the best treatment available.

24 Sep 2009

FDA endorses Covidien's REMS program for EXALGO tablets

Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that it presented information to members of a U.S. Food and Drug Administration (FDA) Advisory Committee on the New Drug Application and proposed Risk Evaluation and Mitigation Strategy (REMS) program for EXALGOTM (hydromorphone HCl extended release) tablets, an opioid formulation.

24 Sep 2009

Hormone leptin can regulate bone mass and suppress appetite

Contrary to the prevailing view, the hormone leptin, which is critical for normal food intake and metabolism, appears to regulate bone mass and suppress appetite by acting mainly through serotonin pathways in the brain, according to a recent study published in Cell by Yale School of Medicine researchers and colleagues at Columbia University. This new finding contradicts the view that leptin acts primarily in the hypothalamus.

24 Sep 2009

IOM study to examine premarket notification program for medical devices

The U.S. Food and Drug Administration today announced that it has commissioned the Institute of Medicine (IOM) to study the premarket notification program used to review and clear certain medical devices marketed in the United States.

24 Sep 2009

Original and creative healthy foods

Claire Criscuolo is the founder and proprietor of legendary health food emporium Claire's Corner Copia, in New Haven, Connecticut (www.clairescornercopia.com). She wants to deliver a message to the rest of the world: Healthy doesn't have to hurt.

24 Sep 2009